MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$120K
Free Cash flow
-$39,424K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of marketable securit...
Net loss
Prepaid expenses and other curre...
Others
Negative Cash Flow Breakdown
Gain on debt extinguishment
Accrued research and development...
Accounts payable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
16,900
-46,664
-47,238
-48,221
Depreciation and amortization expense
-
5
6
6
Depreciation expense
9
-
-
-
Stock-based compensation expense
2,463
6,304
2,898
2,666
In process research and development expenses
-
-
-1
7,476
Amortization of operating lease right-of-use assets
248
227
221
214
Amortization and expense of debt discount and issuance costs
4,955
255
251
248
Amortization of premium on marketable securities, net of accretion of discounts
392
660
1,082
1,585
Change in warrant liability
-1,602
-
-
-
Net realized gain on investments
-
-
5
-
Change in derivative liability
4,113
-
-
-
Loss on disposal of property and equipment
-
-
0
0
Gain on debt extinguishment
43,846
-
-
-
Receivable from contracts with collaborators
-3,147
-2,975
2,984
1,664
Prepaid expenses and other current assets
-6,475
-2,416
3,963
-879
Other assets
31
-10
1
24
Operating lease liabilities
248
227
222
205
Accounts payable
-4,591
6,156
4,822
-795
Accrued expenses and other current liabilities
-1,163
-234
-223
1,308
Accrued research and development expenses
-7,715
-4,267
3,926
2,135
Accrued compensation and benefits
-3,586
1,435
-759
2,809
Contract liabilities
-3,418
-8,952
-1,460
-3,914
Accrued interest expense
-2,911
2,500
-2,500
2,500
Net cash used in operating activities
-39,424
-38,721
-48,314
-36,167
Purchase of marketable securities
0
24,994
20,988
29,586
Maturities of marketable securities
42,700
66,600
87,000
46,600
Sales of marketable securities
-
-
7,144
-
Purchase of property and equipment
0
0
0
0
Net cash provided by investing activities
42,700
41,606
73,156
17,014
Payment of debt issuance costs in connection with the exchange of the 2027 notes
1,963
-
-
-
Proceeds from issuance of common stock and warrants in a private offering, net of offering costs
-
-
0
-
Payment of equity issuance costs in connection with the exchange of the 2027 notes
1,181
-
-
-
Proceeds from issuance of common stock pursuant to employee stock purchase plan
0
292
-1
469
Proceeds from the exercise of stock options
0
220
1,239
465
Proceeds from the exercise of warrants
-
-
2,717
938
Proceeds from grant of equity option pursuant to chiesi collaboration agreement
-
-
-
0
Proceeds from issuance of equity option pursuant to stock purchase agreement
-
-
0
-
Principal repayments of long-term debt
-
-
0
0
Net cash provided by (used in) financing activities
-3,144
512
3,955
1,872
Effect of exchange rate changes on cash and cash equivalents
-12
-101
2
-95
Net increase (decrease) in cash and cash equivalents
120
3,296
28,799
-17,376
Cash and cash equivalents, at the beginning of the period
41,028
37,732
8,933
46,074
Cash and cash equivalents, at the end of the period
41,148
41,028
37,732
8,933
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of marketable
securities
$42,700K
(-82.41%↓ Y/Y)
Net cash provided by
investing activities
$42,700K
(-35.49%↓ Y/Y)
Net increase
(decrease) in cash and cash...
$120K
(100.61%↑ Y/Y)
Canceled cashflow
$42,580K
Net loss
$16,900K
(122.56%↑ Y/Y)
Prepaid expenses and
other current assets
-$6,475K
(-220.60%↓ Y/Y)
Amortization and expense of
debt discount and...
$4,955K
(919.55%↑ Y/Y)
Receivable from contracts
with collaborators
-$3,147K
(-240.43%↓ Y/Y)
Stock-based compensation
expense
$2,463K
(-50.65%↓ Y/Y)
Amortization of operating
lease right-of-use...
$248K
(-54.33%↓ Y/Y)
Depreciation expense
$9K
Net cash used in
operating activities
-$39,424K
(54.57%↑ Y/Y)
Net cash provided by
(used in) financing...
-$3,144K
(-625.75%↓ Y/Y)
Effect of exchange rate
changes on cash and cash...
-$12K
(-105.13%↓ Y/Y)
Canceled cashflow
$34,197K
Gain on debt
extinguishment
$43,846K
Payment of debt issuance
costs in connection...
$1,963K
Payment of equity
issuance costs in...
$1,181K
Accrued research and
development expenses
-$7,715K
(-249.92%↓ Y/Y)
Accounts payable
-$4,591K
(32.23%↑ Y/Y)
Change in derivative
liability
$4,113K
Accrued compensation
and benefits
-$3,586K
(-26.53%↓ Y/Y)
Contract liabilities
-$3,418K
(-259.03%↓ Y/Y)
Accrued interest
expense
-$2,911K
Change in warrant
liability
-$1,602K
Accrued expenses and
other current...
-$1,163K
(-420.39%↓ Y/Y)
Amortization of premium on
marketable securities, net...
$392K
(-91.50%↓ Y/Y)
Operating lease
liabilities
$248K
(-53.56%↓ Y/Y)
Other assets
$31K
(-69.00%↓ Y/Y)
Buy us a coffee
Gossamer Bio, Inc. (GOSS)
Gossamer Bio, Inc. (GOSS)